CompletedEarly Phase 1NCT05620901
DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia
Studying Coats disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Lejla Vajzovic, MD, FASRS
- Principal Investigator
- Lejla Vajzovic, MD, M.DDuke Eye Center
- Intervention
- Dextenza 0.4Mg Ophthalmic Insert(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 3-17 years · All sexes
- Timeline
- 2023 – 2025
Study locations (1)
- Duke Eye Center, Durham, North Carolina, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05620901 on ClinicalTrials.govOther trials for Coats disease
Additional recruiting or active studies for the same condition.